Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of budesonide + glycopyrronium + formoterol MDI versus budesonide + formoterol MDIs in inadequately controlled asthma
2020-001521-31Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide, glycopyrronium and formoterol in asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Primary end point(s) of D5982C00008. Started Jan 2021; status: active.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2020-001521-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001521-31.